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In the last few years we have encountered some remarkable instances in which 
transplanted mouse leukemias that elicit no discernible resistance in mice of the 
same inbred strain have been strongly rejected by F1 hybrid recipients. As de- 
scribed below, a detailed study of one such system revealed that the leukemia 
cells carry a  strong leukemia-related transplantation  antigen  (called X.1)  to 
which  the inbred host  of origin appears  genetically incapable of responding. 
Hybrids are evidently resistant to the same leukemia cells because they possess 
appropriate Ir (immune response)  1 genes, one of these being linked to H-2, in- 
troduced by the outcross parent. The results imply an immunological role for 
the Rgv-1 (resistance to Gross virus) locus (ref. 1 for review) in linkage group 
IX (LG IX). 
Materials and Methods 
Mice.--With the exception of B10  and B10.D2  (new)  (purchased from Jackson Labora- 
tory, Bar Harbor, Maine), these were all obtained from our own colonies. 
Leukemias.--The  two BALB/c  (BALB)  leukemias  that  are  most crucial  to  this study 
have the following  history. Both were induced by X  radiation in BALB  mice of our own 
colonies  and  have  been  transplanted in  these mice ever  since:  (a)  BALB.RLoZl  (BALB 
radiation leukemia male 1) was induced by X radiation in 1962, soon converted to the ascites 
form, and has been passaged serially about 175 times, interrupted by a period of frozen  storage 
(abbreviated RLo  z 1).  (b) BALB.RL Q 1 was similarly induced in 1971, and is now in its 15th 
passage; it also has been stored frozen (abbreviated RL Q 1). 
Cytotoxicity Test.--As described previously (2) ; the source of complement was rabbit serum 
selected for low  toxicity and  high complement activity, diluted  1/3  or  1/4,  preabsorption 
with mouse cells proving unnecessary for the purposes of this study. 
Immunoelectron Microsco~y.--Details  of the method used are given in ref. 3. 
* This work supported in part by National Cancer Institute grant CA 08748. 
:~ Fellow obthe Damon Runyon Fund. 
1 Abbre'dations used in this paper: B6,  C57BL/6; BALB, BALB/c; Ir, Immune response; 
LG, linkage group; MuLV,  murine leukemia  virus; Rgv-1, Resistance to  gross virus-l; RL, 
radiation leukemia. 
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RESULTS 
Resistance of  (BALB  X  B6)  and Reciprocal Hybrid Mice to  Challenge  with 
BALB Leukemia Cells.--Table I  shows that most (BALB X  B6) and reciprocal 
hybrid mice, male and female, rejected up to 3 M  106 RLC 1 or 1 M  l0  s RL ~ 1 
BALB  leukemia cells  (highest initial  inoculum  tested)  given subcutaneously, 
although  BALB  mice  have  never  survived inocula of  1  X  104  RL  cells  (the 
lowest number tested); we have observed no instance of a BALB mouse resist- 
TABLE I 
Resistance of (BALB  X  B6)  and Reciprocal Hybrid Mice to the BALB  Leukemias RLC1 
and RL ~- 1 Inoculated Subcutaneously* (Summary of All Experiments) 
Recipient~  Sex 
Number  of leukemia  cells inoculated 
I  X  10  4  5  X  10  4  1  X  10 b  2  X  I0S  5  X  10~  1  X  l0 s  3  XI0 6 
BALB leukemia 
RLC1 
(BALB X  B6)  9  0/8  0/8 
(BALB X B6)  o" 
(B6 X BALB)  ? 
(B6 X  BALB)  C 
BALB  9  3/3  6/6 
BALB  C  3/3 
BALB leukemia 
RLgl 
(BALB X B6)  9  0/14 
(BALB X  B6)  C  0/4 
BALB  9  11/11 
BALB  C  4/4 
mice dead/total 
1/17  0/8  4/50  0/8 
1/16  2/5 
0/10 
0/7  0/7 
8/8  3/3  36/36  5/5 
m/lO  5/5 
* The inoculum was made subcutaneously into shaved skin on the flank. In  the  hybrid 
the inoculum usually grew to palpable size (up to about 1 cm diameter) and then regressed. 
Most hybrids thereafter resisted sequential inocula of up to 200 X  106 leukemia cells (highest 
number tested) given intraperitoneally. These hyperimmunized mice were the source of X.1 
antiserum. 
:~ The female parent of each cross is the strain shown first. 
ant to RLo  ~ 1 or RL 9  1. By progressively increased inocula, the hybrids could 
be immunized to challenge with more than 200 X  106 leukemia cells. 
Resistance vs. Susceptibility of Different BALB Hybrids: Association with H-2 
(LG IX).--  Some  strains when  crossed to  BALB  confer resistance  to  BALB 
leukemia RLc? 1 cells whereas others do not (Table II). We refer to the former 
as "responder" strains, and the latter strains, which confer little or not resist- 
ance, as "nonresponders." Strains B10 and AKR/H-2 b are responders, but their 
congenic partner strains B10.D2  and AKR, differing respectively only for the 
region of H-2,  are nonresponders.  Therefore the major locus conferring resist- 
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TABLE II 
Different  Mouse  Strains  Classified  as  X.1  Respon3ers  or  X.1  Nonrespouders  (Including 
Low  Responders)  According  to  Their  Capacity,  when  Crossed to  BALB, to Confer 
Resistance  to  RLo~I  BALB  Leukemia  Cells* 
Strain 
B6 
B6 
B6 
B6 
BIO 
AKR/H-f~§ 
lITI 
HTI 
C58 
I 
X.1 Responders  X.1 Nonresponders 
ttybridl  recipient 
(BALB  X  B6) 9 
(BALB  X  B6)c? 
(B6 X  BALB)9 
(B6 X  BALB)o  ~ 
(B10  X  BALB) ? 
(BALB X  AKR/H 2  b) 9 
(BALB  X  tITI)9 
(BALB  X  HTI)o  ~ 
(BALB X  C58)9 
(BALB  X  I)9 
Mice 
dead/ 
total 
4/50 
1/16 
0/10 
0/7 
1/20 
2/'9 
2/13 
0/S 
2/10 
0/4 
Strain 
BALB 9 
BALBc~ 
B10.D2§ 
I)BA/2  (-D2) 
AKR 
AKR 
HTG 
IITG 
C3tt/An 
A 
A 
Hybrid  recipient 
Control 
Control 
(BI0.D2  X  BALB) 9 
(BALB  X  DBA/2) 9 
(BALB  X  AKR)9 
(BALB  X  AKR)c  ~1 
(BALB X  HTG) 9 
(BALB X  ttTG)C 
(BALB  X  C3It/An)9 
(BALB  X  A)9 
(BALB  X  A)fl 
Mice 
dead/ 
total 
36/36 
I0/I0 
9/10 
18/18 
9/9 
5/5 
11/11 
4/4 
6/8 
6/7 
4/5 
* l  X  10  6 cells subcutaneously  to female recipients, 2 X  10  5 to males. 
~: The female parent of each cross is of the strain shown first. 
§ Congenic stocks differing from base strain only at the 1t-2 region of linkage group IX. Interpretation:  (a) 
Linkage group IX contains an immune response (Ir) locus conferring ability to respond  to the leukemia-related 
transplantation  antigen X.1  and  so to  reject X.l-positive  leukemia cells.  (b)  Results  with  the  H  2  crossover 
stocks HTI vs. HTG (4) place this Ir locus in the K region of H-2 [HTI shares its K region with B6 (a responder) ; 
HTG shares its K  region with BALB  (a nonresponder)]. 
Two entries in Table II suggest that the resistance locus is in the K  rather 
than D  region of H-2. HTG is an H-2 crossover stock  sharing  its H-2(K)  but 
not its H-2(D) region with BALB (4) ; it is a nonresponder. On the other hand, 
HTI, a  different 11-2  crossover stock, possibly shares  its H-2(D)  region with 
BALB  (nonresponder) and has the same K  region as B6, which is a responder, 
and is itself a responder. 
Table III summarizes experiments in which  BALB  backcross mice derived 
from crosses with B6 were typed for H-2 and then challenged with one of the 
BALB leukemias RLc~ 1 or RL 9 1. There was a close correlation between H-2 
type and capacity to resist challenge with the leukemia cells; therefore, again 
a  substantial part of the resistance of the hybrid can be traced to LG IX. The 
presence of a second resistance locus in B6, not in LG IX, is suggested by the 
finding that a few H-2-compatible mice survived. 
Serological  Typing.--Pooled  antisera  (called  "anti-X.l")  were obtained  by 
tail-bleeding (BALB X  B6) mice that had received 5-15 inoculations of RLc~ 1 
cells, in numbers rising from 1 X  10  5 to 2 X  10  s intraperitoneally (see Table I). 
These antisera were positive in cytotoxicity tests with three BALB leukemias 
and one strain A leukemia (Fig.  1 and Table IV). [Similar results are given by 
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TABLE  III 
Further  Identification  of the Linkage  Group IX Ir Locus  That  Confers Resistance  to 
X.1-Positive  (X.1  +)  Leukemia  Cells. Challenge  of  H-2-Typed  BALB  Backcross 
Mice* with BALB Leukemia  RLcP1 or RL9 1 
Recipients* 
Exp. no.  Inoculum  H-2d/H-3 d  H-3d/H-2 ~ 
C  ~  C 
mice dead~total 
i  1 X  106 RLo~I cells  18/20  4/18 
2  1 X  10 a RL9 1 cells  9/12  12/12  4/13  7/13 
3:~  1 X  105RL9 1 cells  10/13  9/1l  2/13  1/13 
* The recipients were backcross mice of the type BALB X  (BALB X B6) in vartous mating 
combinations (which did not significantly  affect the outcome  and are therefore  not treated 
separately). 
~c In this experiment the recipients had been preimmunized with the H-2-incompatible 
X.1 + strain A leukemia RADA1  (see Table IV). Interpretation: (a) Linkage group IX con- 
tains an immune response (It)  locus conferring  ability to respond to the leukemia-related 
transplantation antigen X.1.  (b) This Ir (IX) locus is a major but not the only determinant 
of X.1 resistance in hybrid recipients. 
X.l-typing of leukemias  and other tumors by absorplhm:  Several leukemias and 
transplanted  tumors  of other kinds were  typed for X.1  by absorption of X.1 
antiserum diluted to near the end point, a sensitive serological method in vitro 
for  detecting cell-surface antigens.  The  results  are  sumnqarized  in  Table  IV, 
where it can be seen that X.1  antigen does not originate from passage A  Gross 
virus. 
X.1 typing of normal mice by absorption in vivo: X.1  antigen was not demon- 
strable on thymocytes, lymph node cells, spleen, or bone marrow of young adult 
mice of strains with  a  high incidence of leukemia  (AKR,  C58),  or of mice of 
other  strains  (including BALB),  either  by  the  direct  cytotoxicity test or  by 
absorption. 
With AKR cells, however, the results of absorption in vitro were equivocal, 
suggesting that X.1  antigen might be present in small amounts in normal AKR 
mice. For this reason AKR and other mouse strains were typed for X.1  by ab- 
sorption in vivo.  Fig. 2  A  illustrates how  a  selected standard  amount  of X.1 
antiserum was found to be rapidly cleared by AKR mice but not by B6 mice. 
Table V  shows mouse strains classified as X.1 + or X.1- on the basis of absorp- 
tion in vivo. Here it is seen that with the one exception of strain 129 the X.1 + 
strains  are  all  those  that  are  life-long producers  of  murine  leukemia  virus 
(MuLV), which is highly suggestive that X.1  is associated with MuLV. This is 
further emphasized by the fact that C3Hf/Fg-Law alone of the three C3H  sub- 
lines tested was X.I+; this subline is noted for having acquired a high  titer of 
MuLV and a high incidence of leukemia at some point in its history. 
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FZG. 1. Cytotoxicity tests with X.1  antiserum on four mouse leukemias. 
treatment of AKR mice with cortisone greatly reduces their capacity to absorb 
X.1  antibody, the inference being that X.1 is represented primarily if not ex- 
clusively on lymphoid cells (see ref. 5 for the effect of cortisone on absorption 
of various alloantibodies in vivo). 
Passive Immunization  against BALB.RL Cells with X.1 Antiserum.--Passive 
protection against RL 9 1 BALB leukemia cells was tested for in (a) adult mice 
receiving X.1 antiserum by injection, and (b) the suckling progeny of (BALB X 
B6) mothers immunized with RL 9 1 and mated to BALB males.  (The latter 
test has been applied previously with success in a  similar context [ref.  6].)  In 
both instances  there was  complete suppression  (Table VI);  a  control  serum 
prepared against MOPC-70A BALB myeloma cells (used because it was judged 
the most  appropriate  antiserum  available  against  an X.1- BALB malignant 
cell) afforded no protection (Table VI). 
Cytotoxic Antibodies in the Serum of Xormal (BALB X  B6) Mice.--The serum 
of many (BALB X  B6) mice contains cytotoxic antibody against BALB.RLc? 1 
leukemia cells. This presumably is an anti-X.1 antibody. Normal (BALB X  B6) 
serum also frequently contains antibody to leukemia EL4 (C57BL). But this 
latter antibody is not completely removed by absorption with RLc? 1 cells, and 
therefore EL4 carries an antigen that does not belong to the X.1  system. 
It is not surprising therefore that X.1 antisera are cytotoxic for leukemia EL4 
although EL4 does not absorb activity from X.1 antiserum. The probability is 
that X.1 antiserum contains the naturally occurring cytotoxic antibody to EL4 
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TABLE  IV 
Leukemlas and Other Tumors* Classified as X.1 + or X.1- 
Strain of origin  Description 
X.I type 
By direct  By absorp- 
cytotoxicity test  tion in vitro 
BALB 
AKR 
B6 
C3H 
(sub-line?) 
I 
RLc~ 1, RL 9 1, RL 9 2 (radiation-induced  +  + 
leukemias) 
Meth A (ascites sarcoma; chemically in-  --  -- 
duced); MOPC-70A, S19 (myelomas) 
RADA1 (radiation-induced leukemia)  +  + 
ASL1, ASL8 (spontaneous leukemias)  --  -- 
15 primary spontaneous leukemias  ±/+  + 
K36 (longtransplanted  ascites leukemia){  --  -- 
Ec~G2 (leukemia induced by passage A  --  -- 
Gross virus) 
ERLD (radiation-induced leukemia)  --  -- 
BP8 (ascites sarcoma)  --  -- 
1-29 (spontaneous leukemia)  --  -- 
* With the exception of MOPC-70A, S19, and BP8, all these arose in mice of our colonies; 
details of their origins appear in various previous papers from this laboratory  (MS-KCC). 
:~ This leukemia is carried in (B6  X  AKR)F1 hybrids, which may account for its being 
X.1- (see text). 
Partial Resistance of RLcr 1 BA LB Leukemia Cells after Passage in (BALB  X 
B6)  Hybrids.--A  line of RLo  ~ 1 cells that  had  been passed  eight times intra- 
peritoneally in untreated (BALB  X  B6) mice was found to exhibit greatly re- 
duced sensitivity to cytotoxic X.1 antiserum and to be more resistant to rejec- 
tion  by  (BALB  X  B6)  recipients.  In  the  latter  test,  4/5  (BALB  X  B6) 
recipients survived the standard challenge inoculum of 1 X  l0  G  RLo  z 1 BALB 
leukemia cells as opposed to  1/5  (BALB X  B6) recipients challenged with the 
1 X  106 cells of the Fl-passaged line. Quantitative absorption of X.1 antiserum 
(for method see ref. 5)  shows the Ft-passaged line to contain only 15-20% of 
the X. 1 antigen carried by the original BALB-passaged line. A count of C-type 
particles in electron micrographs, carried out by Dr.  C.  Stackpole  (of  Sloan- 
Kettering Institute), suggests a corresponding decrease in the number of virions 
produced by the relatively resistant Fl-passaged Line. 
Immunoelectron  Microscopy with  X.1  Antisera.--Fig.  3 is an electron micro- SATO~ BOYSE~ AOKI~ IRITANI~  AND  OLD  599 
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FIG.  2.  Clearance of X.1 antibody injected into B6 or AKR mice  (A) or into AKR mice 
treated with cortisone (B). Each group of eight mice, 6-7 wk old, of the same sex and similar 
weights, received X.1 antiserum (same pool)  intravenously, 0.6 ml for A  and 0.3 ml for B. 
Serum samples were taken from each mouse at intervals as indicated  (A) or after  1 h  (B) 
and titrated for residual cytotoxic antibody against RLoZl cells  (after heating at 56°C  for 
30 min to reduce the anticomplementary action of mouse serum). The initial titer of the X. 1 
antiserum pool [(BALB  X  B6)F1 anti-BALB RLoZl  leukemia cells]  was  1/128  (end point 
500~o RLoZl ceils lysed). The cortisone-treated mice (B) received 25 mg of cortisone acetate 
intramuscularly 3 days before injection of antiserum. Interpretation:  (a) Normal AKR mice 
express X.1  antigen.  (b)  X.1  antigen is  expressed  mainly on lymphoid  tissues,  hence  the 
greatly reduced clearance after cortisone. (c) B6 mice do not express X.1 antigen. 
graph illustrating an RLc~ 1 cell with budding virions. The sites of X.1 antigen 
are shown by the marker southern bean mosaic virus according to the hybrid 
antibody  method  (8). There is labeling of sectors  of the cell surface  and  also 
of virions. 
Preliminary Results with 1-29, a Second Leukemia That Is Rejected by Hybrid 
Recipients.--This leukemia arose spontaneously in a  mouse of our I  colony in 
1961.  It has undergone  about 130 passages and has been stored frozen.  It is 
rejected strongly by some I  hybrids, but never by I  mice, and a cytotoxic an- 
tibody is produced that is not identical with anti-X.1; as shown in Table IV, 
leukemia 1-29 is X.1-. 
DISCUSSION 
The most remarkable feature of the X.1 system in the two BALB leukemias 
RLo  z 1 and RL 9 1 is the considerable strength of the rejection response of re- 
sistant hybrids such as (BALB X  B6) in the face of an apparently total lack of 
any immune response in syngeneic BALB  hosts.  Resistance to inoculation  of 
2  X  l0  s intraperitoneal  RLc?I cells is the  rule in  (BALB  X  B6)  recipients 
whose resistance has been built up by progressive immunization, and no doubt 600  LEUKEML~-ASSOCIATED TRANSPLANTATION ANTIGEN  X.1 
TABLE V 
Mouse Strains Classified as X.1  + or X.I-(*) 
X.1  +  X.1- 
AKR (21;) 
AKR/[I-2b§  (6) 
AKR/tf-2~§ (4) 
C58 (6) 
NZB (2, old) 
129 (8) 
129/Gix-§ (2) 
C3Hf/Figge-Law (4) 
A (4) 
A.BY§ (2) 
A/TL-§ (3) 
BALB (8) 
DBA/2 (3) 
B6 (8) 
B6/Gtx~§  (2) 
B6/Ly-I.1 § (3) 
B6/Ly-2.1§ (8) 
B6/H-2k§ (5) 
C3H/An (3) 
C3Hf/Bi (3, young) 
GR/A (2) 
i  (2) 
SJL (2) 
SWR (2) 
CBA.T6 (2) 
* According to clearance of X.1 antibody in vivo as illustrated in Fig. 2. Each mouse re- 
ceived 0.25 ml of an X.1 antiserum pool with a titer of 1/64 against RLo~I cells; serum re- 
covered 30 min later was titrated against RLo  ~ 1 ceils starting at a dilution of 1/2. There is a 
clear distinction between X.1  + and X.1- strains: with X.1  + mice the serum recovered shows 
very little cytotoxic activity (always <40% lysis at 1/2); serum from X.1- mice shows 70- 
80% cells lysed at 1/2 and demonstrable iysis up to 1/8-1/16. 
:~ Number of mice tested. 
§ Congenic strains differing  from the background strain only in the region of the locus 
indicated. 
even larger inocula would have been rejected. So X.1 is a highly effective trans- 
plantation antigen, but one to which the BALB host is evidently unresponsive. 
We shall not undertake here to comment generally on the subject of resistance of hybrid 
mice to  cells  of parental origin. Useful reviews  and extensive references  are provided  by 
Huemer (9) and Bennett (10). 
Genetics of the Immune Response to X.1  + Leukemia Cells.--A large part of the 
resistance in (BALB  X  B6)  hybrids is conferred by a  locus in the K  region of 
H-2. Very probably this is Rgv-1, which is known to lie in this region and has 
a  dominant allele conferring resistance to leukemogenesis bv inoculated Gross 
MuLV (1). In that event the mechanism by which Rgv-1 controls susceptibility 
to MuLV is immunological and it may provisionally be classed with the Ir (Im- 
mune response)  genes  that  are  linked to  the  K  end of H-2 and  are known to 
determine high vs. low response to a number of antigens (11). 
As more than one Ir locus may be involved in the imnmne response to X.1, SATO,  BOYSE,  AOKI~  IRITANI,  AND  OLD  601 
TABLE VI  -. 
Passive Immunization with X.1 Antibody: Protection against Challenge with X.1  + 
Leukemia Cells 
Recipients 
Challenged 
with RL 91 
BALB 
leukemia 
cells 
Experiment l 
AdultBALB  9 9  1  X  105 
Experiment 2 
Newborn progeny  1  )<  104 
of immune  q  q * 
5  X  10  4 
BALB  (aged 1 day)  1 X  104 
5  X  104 
! 
Mice 
Antiserum  ! dead/ 
I total 
! 
Anti-X.  1  10/3 
Anti-PC.1  (control)  3/3 
None  3/3 
Anti-X.1 (by maternal  0/11 
transmission) 
0/12 
None  16/6 
6/6 
I 
Time to death 
days 
All survived 
33, 33, 36 
36, 41, 47 
All survived 
All survived 
41, 41, 42, 42, 48, 49 
28, 34, 34, 36, 36, 36 
Anti-X.1 serum  =  (BALB  X  B6)F1  anfi-RLoZl BALB  leukemia cells,  administered 
intraperitoneally (0.3 inl)  3-4 h  before  challenge  with  RL 9 1 BALB  leukemia cells  sub- 
cutaneously.  Anti-PC.1 control serum =  (B6 X DBA/2)F1 anti MOPC-70A BALB myeloma 
cells, administered as above.  This cytotoxic antiserum recognizes PC.1  alloantigen that is 
present on myeloma cells but not on leukemia cells (7). 
* Aged 2-5 days; progeny of (BALB  X  B6)F1  females immunized  against  RL 9 1 leu- 
kemia cells and producing high titers of X.1 antibody (mating was with BALB o  ~ oz). 
it is possible that the resistance of some other hybrids might be due to a  locus 
other than Rgv-1; this would have to be tested in each case by the criterion of 
association with H-2 type. As X.1  antigen is present on  both  virion and  cell 
surface, the resistance to viral leukemogenesis conferred by the relevant Rgv-1 
allele (1) could involve neutralization of MuLV as well as elimination of MuLV- 
infected cells. 
The Relation of X.1  to MuLV.--This  is established by:  (a)  the reaction of 
X.1  antibody with the viral envelope, seen in immunoelectron microscopy, and 
(b)  the finding that mouse strains with a  high incidence of leukemia are X.1 + 
and other strains X.1- (with the exception of strain 129 mice). But X.1  antigen 
distinguishes a sub-type of MuLV distinct from passage A  Gross virus, and the 
serological evidence suggests that it is not the predominant MuLV of AKR and 
other strains with a  high incidence of leukemia, hence the poor representation 
of X.1  antigen in these strains despite their high output of MuLV. 
Naturally Occurring Antibodies to Leukemia Cells in the Serum of (BALB  X 
B6) and Reciprocal Hybrid Mice.--Cytotoxic  antibodies against leukemia cells, 602  LEUKEML~-ASSOCIATED  TRANSPLANTATION  ANTIGEN  X.1 
FiG.  3.  BALBc~RL1  leukemia  ceils  were  reacted  with  X.1  antiserum  and  the  antigen 
sites  marked  with  SBMV  (southern  bean  mosaic virus)  according  to  the  hybrid  antibody 
method  (8).  Small  areas on the ceil  surface, and  the envelope of  the virus, are  labeled  with 
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directed  to X.1  and probably at least one other leukemia-related cell-surface 
antigen, are common in the serum of (BALB)< B6) and reciprocal hybrids. It 
seems likely that these, and similar natural antibodies in other mouse strains, 
originate from exposure of mice bearing the appropriate Rgv/[r alleles to the 
respective sub-types of MuLV, endogenous or exogenous. 
Nomenclature.--  Our choice of "X" in designating this antigenic system re- 
vealed by the immune response of hybrid mice was based on preference for a 
simple and noncommittal provisional notation, and because of certain similari- 
ties to earlier work on leukemia antigens  called X  by Gorer and Amos  (12). 
These antigens, like X.1, were demonstrable by using antibody to protect mice 
against challenge with a  syngeneic leukemia, the antiserum being prepared in 
this  case by immunizing a  second inbred  strain  with  the  leukemia cells.  No 
in vitro serological test for antibody was successful; this may be attributable 
to  the  primitive state of the  cytotoxicity test  at  that  time,  and  to  the  fact 
that  such  antisera contain  various alloantibodies  that must be absorbed out 
before  a  test for anti-X  is  feasible.  The  original X  antigens  were  seemingly 
highly diverse,  each leukemia having a  different one,  even in a  single inbred 
strain;  cross-reactivity was either absent or minimal  (13,  14).  This led  Gorer 
to conclude that X  antigens could not be associated with leukemia virus (13). 
That view  is less  compelling today when  we  have so much  evidence of the 
diversity of MuLV  by such  criteria  as  neutralization  of virus  in  vitro  (see 
ref.  15),  range of host susceptibility  (reviewed in ref.  1),  as well as immuno- 
electron microscopy (3, 16); indeed no fewer than four distinguishable isolates 
of MuLV can be obtained from a single inbred (BALB) mouse (17), and there 
is no reason to think that this is an upper limit.  Gorer did not observe rejec- 
tion  of his  leukemias  by hybrids,  but  he  noted  that  "X  tests"  (i.e.  giving 
antiserum to protect mice against challenge with leukemia cells) were usually 
more effective in hemisyngeneic hybrids than in the syngeneic strain of origin, 
suggesting  augmentation  of resistance  by an  active immune  response in  the 
hybrid. All Gorer's leukemias had been passed for long periods in hybrids and 
may thus have acquired a relative resistance comparable to that of our RLo  z 1 
line  after passage in hybrids,  which  would  also  account  for the weakness of 
protection  by  antibody  in  most of his  experiments.  Gorer noted  in  a  single 
experiment that ability to produce an X  antibody was linked with H-2  (13), 
but the relation of this finding to our observation of H-2-1inked ability to re- 
ject leukemia cells is uncertain  because the former effect was genetically re- 
cessive (13) whereas the latter is dominant, as expected for an Ir gene in LG IX. 
Are X  Systems likely to Be Found in All Leukemias?--This  is an important 
question,  e.g., in its relation to the prospect of using X  antisera to arrive at a 
comprehensive  classification  of  MuLV  that  could  be  used  for  identification 
purposes and thus help in elucidating the biology of these viruses. The second 
case  of strong  hybrid  resistance  that  we  are  studying,  alluded  to  briefly in 
Results  (last  section),  involves the  I  strain  leukemia 1-29,  and  it  is  already 604  LEUKEMIA-ASSOCIATED  TRANSPLANTATION  ANTIGEN  X.1 
apparent  that the 1-29 antigen is not identical  with X.1.  The fact that most 
leukemias  are not strongly rejected  by hybrids might seem to  speak  against 
X  antigens  as  a  general  feature  of leukemias.  But  this  may be  misleading, 
because evidently resistance develops with  relative ease  simply on passage in 
hybrid recipient.  It may be  that X  antigens  are  characteristic  of leukemias 
generally  but  only  uncommonly  act  as  strong  histocompatibility  antigens. 
Future search for other X  systems will therefore not be limited to the criterion 
of strong histoincompatibility  responses  on  the  part  of hybrids,  but  will  in- 
clude  tests  for X  antibodies in hybrids inmmnized with  material  other than 
viable leukemia cells. It remains to be seen whether the presence of X  antigens 
is  invariably  associated  with  production  of  virions. 
By an  "X system" we imply an antigen or set of antigens,  associated with 
leukemia cells,  to which some strains  of mice can respond,  but not the strain 
of origin of the leukemia.  How the features of the X.1  system--(a) presence 
of antigen on virions and cell surface,  (b)  transplantation resistance and anti- 
body production  by hybrid  recipients,  and  (c)  transfer  of resistance  to  leu- 
kemia  cells  by means of antiserum--could  or  should  be  used  as  criteria  for 
defining a class  of  (X)  leukemia  antigens  may be clearer when more of these 
systems have been studied. 
SUMMARY 
Two BALB radiation leukemias are strongly rejected  by hybrids of  BALB 
with  certain  other  mouse  strains,  although  BALB  mice  themselves  exhibit 
no  detectable  resistance  whatever.  Hybrids  immunized  with  progressively 
increased  inocula  are  resistant  to  200 X  106  or  more  leukemia  cells;  their 
serum  is  cytotoxic for  the  leukemia  cells  in  vitro  and  protects  BALB  mice 
against  challenge  with  these  BALB  leukemias.  The  antigenic  system  thus 
identified has been named X.1. 
In  (BALB X  B6)  hybrids the  major determinant  of resistance  was  shown 
to be a B6 gene in the K  region of H-3. This is likely to be the Rgv-1 (Resistance 
to gross virus)  locus of Lilly, which may thus be identified  in  this case as an Ir 
(Immune response) allele conferring ability to respond to X.1 antigen on MuLV 
and leukemia cells,  and so responsible for production of X.1  antibody and the 
rejection of X.1 + leukemia cells by hybrid mice. 
Immunoelectron microscopy with X.1  antiserum (from immunized hybrids) 
shows labeling  both  on  the  cell  surface  and  on virions produced by the leu- 
kemia  cells.  It is  not known  whether X.1  comprises only one or  more  than 
one antigen. 
Three  radiation-induced  BALB  leukemias,  one  A  strain  radiation-induced 
leukemia,  and  15/15  AKR  primary spontaneous  leukemias were  typed X.1  + 
by the  cytotoxicity test.  Several  other leukemias,  including  one induced  by 
passage  A  Gross  virus  and  one  long-transplanted  AKR  ascites  leukemia 
carried in  (B6 X  AKR)FI hybrids, were X.I-. Normal mice of strains with a SATO, BOYSE, AOKI, IRITANI, AND  OLD  605 
high  incidence  of leukemia  and  one  other  strain  (129)  express  X.1  antigen, 
but evidently in amounts too small for certain detection in vitro; by the method 
of absorption  in vivo, however,  these  strains  could be  typed X.1 +  and  other 
strains X.1-. 
We ascribe the X.1  antigen system tentatively to a  sub-type of MuLV that 
is  not  passage  A  Gross virus  and  is  probably not  the  dominant  sub-type in 
strains with a high incidence of leukemia. 
After repeated passage in hybrids, one of the BALB leukemias became rela- 
tively  resistant  to  rejection  by  the  hybrid,  partially  lost  its  sensitivity  to 
X.1  antiserum in vitro, and in electron micrographs was seen to produce fewer 
virions. 
The  serum  of  untreated  (BALB X  B6)  hybrids  often  contains  cytotoxic 
antibody  against  leukemia  cells,  some  of it  probably  anti-X.1.  But  another 
commonly occurring  antibody,  which  is  cytotoxic for C57BL leukemia  EL4, 
appears  to  belong  to  another  (undefined)  system. 
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